On The Pen GLP-1 News

By Dave Knapp GLP-1 Industry Insider

On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of

... more

4.9

351351 ratings

FAQs about On The Pen GLP-1 News:

How many episodes does On The Pen GLP-1 News have?

The podcast currently has 210 episodes available.

Best of On The Pen GLP-1 News

The most played episodes among Podcast App listeners.

Number 1: GLP-1 Coverage Is COLLAPSING in 2027
GLP-1 access is getting tighter just as obesity treatment is becoming more effective, more affordable, and more important to public health. In this episode of the On The Pen Podcast, Dave Knapp breaks down two of the biggest GLP-1 stories of the week: why most states are opting out of the Trump administration’s new Medicaid obesity-drug coverage model, and why employers are preparing to cut GLP-1 coverage in 2027. We also dig into the growing conversation around GLP-1 microdosing after Real Housewives of Orange County star Emily Simpson described using a lower-frequency maintenance strategy after losing around 50 pounds. Could lower-dose or intermittent GLP-1 therapy eventually become a legitimate maintenance tool? Could it help lower long-term healthcare costs? And could earlier, lower-intensity treatment eventually become a form of prophylaxis against obesity-related disease? This episode covers Medicaid GLP-1 coverage, the BALANCE model, Zepbound coverage, Wegovy coverage, employer insurance changes, compounded GLP-1 access, GLP-1 microdosing, obesity maintenance, semaglutide, tirzepatide, metabolic disease prevention, obesity medicine, healthcare costs, and the future of GLP-1 treatment. If you take Ozempic, Wegovy, Mounjaro, Zepbound, compounded semaglutide, compounded tirzepatide, or simply follow the rapidly changing world of obesity medicine, this is a conversation you need to hear. Subscribe to On The Pen for breaking GLP-1 news, obesity medicine updates, access and insurance coverage news, new weight-loss drugs, clinical research, and patient advocacy. More from On The Pen: https://linktr.ee/manonthemounjaro #GLP1 #Ozempic #Wegovy #Mounjaro #Zepbound #Semaglutide #Tirzepatide #Microdosing #ObesityMedicine #WeightLoss #Medicaid #HealthInsurance #CompoundedGLP1 #Obesity #GLP1News
August 26, 202635min
Number 2: $50 Zepbound Incoming? China Has US in a GLP-1 “Chokehold”
Could GLP-1 medications eventually cost just $40 to $50 per month? Hims & Hers CEO Andrew Dudum thinks so, and if he’s right, it could completely change access to obesity treatment in America. But getting there may depend on something most patients have never heard of: the global peptide manufacturing supply chain. In this episode of The Weekly Dose from On The Pen, Dave Knapp, Man on the Mounjaro, breaks down one of the biggest weeks in GLP-1 and obesity medicine news, including the surprising role of Chinese pharmaceutical manufacturer WuXi AppTec, which Bloomberg described as having a “GLP-1 chokehold” while U.S. policymakers wrestle with reducing America’s dependence on Chinese biotechnology. We also dig into one of the strangest GLP-1 stories of the year. Amylyx Pharmaceuticals just reported positive Phase 3 results for avexitide, a GLP-1 receptor antagonist, meaning it actually BLOCKS GLP-1. The drug reduced serious hypoglycemic events by 55% in patients with post-bariatric hypoglycemia, a debilitating condition that can occur after gastric bypass surgery. Then we get personal. Online personality Clavicular recently described becoming apathetic while taking a high dose of retatrutide, renewing the conversation around GLP-1 medications, anhedonia, emotional blunting, dopamine and reward signaling. Dave has firsthand experience with anhedonia during GLP-1 treatment and previously discussed that experience as part of coverage on the Today Show. At what point does turning down food noise start turning down everything else? We also examine Serena Williams’ return to professional tennis while openly using Zepbound (tirzepatide) and the growing debate over whether GLP-1 medications could ever be considered performance-enhancing drugs in professional sports. Plus, new research suggests GLP-1 medications and significant weight loss may improve testosterone levels and fertility markers in men with obesity-related low testosterone, raising important questions about metabolic health, hypogonadism and when testosterone replacement therapy may or may not be appropriate. In this episode: 💉 Could Ozempic, Wegovy, Mounjaro and Zepbound eventually cost $40 to $50 per month? 🇨🇳 Why WuXi AppTec and China matter to the global GLP-1 supply chain 💰 How manufacturing capacity could determine future GLP-1 prices 🧬 Amylyx avexitide Phase 3 results and the “anti-GLP-1” 🩸 Post-bariatric hypoglycemia after gastric bypass surgery 🧠 Retatrutide, anhedonia, apathy and emotional blunting ⚖️ Why anecdotes about GLP-1 side effects still need scientific context 🎾 Serena Williams, Zepbound and the performance-enhancing drug debate 💪 GLP-1 medications, weight loss and testosterone in men 🧬 Obesity, metabolic health, fertility and hypogonadism The goal here isn’t to cheerlead GLP-1 medications or scare patients away from them. It’s to understand what the headlines actually mean so patients can have better conversations with their healthcare providers. If GLP-1 medications were available for $40 to $50 cash per month without insurance, would that change your ability to stay on treatment? Let me know in the comments. And if you’ve experienced anhedonia or emotional flattening while taking a GLP-1 medication, particularly after increasing your dose, I’d be interested in hearing about your experience as well. The Weekly Dose is shot live in the Bask Health Studio. Learn more at bask.health Thanks to VoaFit and the MyLevel app for sponsoring the podcast. Learn more at voafit.com/otp 🔗 Follow On The Pen, find our newsletter, resources and all of my social channels: otplinks.com On The Pen covers breaking news and patient-focused reporting on obesity medicine, GLP-1 medications, Ozempic, Wegovy, Mounjaro, Zepbound, tirzepatide, semaglutide, retatrutide, compounded GLP-1 medications, obesity treatment, type 2 diabetes, metabolic health and the next generation of obesity medications.
August 18, 202646min
Number 3: 200 GLP-1 Deaths, Chrissy Metz & a Stunning Harvard Study
Https://www.otplinks.com Based on the transcript flow, here’s a clean YouTube description with chapter timestamps. The transcript itself doesn’t include timecodes, so these are estimated from speaking pace and topic position. A GLP-1 Death_ Chrissy Metz & a Stunning Harvard Study.txt More than 200 deaths in the UK have now been reported in association with GLP-1 medications, including the heartbreaking death of a 19-year-old woman taking tirzepatide. But the headline does NOT tell the whole story. Today, we unpack what those 216 reports actually mean, what investigators found in the death of Josephine Nassar, and why adverse-event reports are very different from proving a medication caused a death. Plus, This Is Us star Chrissy Metz reveals she is using a GLP-1 to treat obesity, and I think what she did deserves a lot more respect than she’s getting. Then we dig into a stunning new Harvard working paper examining what happened to women’s employment and relationship outcomes after starting GLP-1 treatment, and Starbucks becomes the latest major employer to pull GLP-1 coverage for obesity. This is a BIG episode. ⏱️ CHAPTERS 00:00 The GLP-1 headlines you need to know 01:40 VoaFit / MyLevel 03:30 200+ GLP-1 deaths reported in the UK 04:25 The tragic death of 19-year-old Josephine Nassar 09:40 The hidden heart condition found after her death 12:30 Did tirzepatide contribute to her death? 15:35 What the UK’s 216 GLP-1 death reports actually mean 19:15 Pancreatitis and how regulators identify real safety signals 22:35 Chrissy Metz reveals she’s taking a GLP-1 24:35 Why Chrissy Metz’s decision to tell the truth was incredibly brave 27:05 Harvard’s stunning “Obesity Penalty” study 30:30 Starbucks drops GLP-1 coverage for obesity 33:10 What happens when employers stop paying for these drugs? 34:15 Final thoughts and your call to action If you’ve lost significant weight, I want to hear from you: Did people start treating you differently? And if your employer stopped covering your GLP-1, would you consider changing jobs to keep access to treatment? 👇 Drop your experience in the comments. 🔗 Keep up with everything On The Pen: linktr.ee/manonthemounjaro On The Pen brings you the stories and information that empower you to have better conversations with your doctor. Subscribe and join us live every Monday, Wednesday and Friday at 11 AM Central / 12 PM Eastern. #GLP1 #Mounjaro #Zepbound #Ozempic #Wegovy #Tirzepatide #WeightLoss #Obesity #ChrissyMetz If you give me the actual final runtime of the uploaded video, I can tighten those timestamps much closer to the real chapter breaks.
August 12, 202632min
Number 4: Eli Lilly Earnings Call Recap: Retatrutide News
https://www.otplinks.com
August 07, 20261h
Number 5: We’re Solving Obesity. Now Who Pays for It?
This week on On The Pen, the GLP-1 story is moving in two very different directions. The Fifth Circuit handed FDA major wins in the fight over semaglutide and tirzepatide shortages, FDA updated its consumer guidance around compounded GLP-1 medications and multi-dose vials, and employers continue questioning whether they can afford obesity-drug coverage. At the same time, the medical case for these medications keeps getting stronger. We break down Mounjaro’s new cardiovascular indication and what preventing heart attacks and strokes could mean for the true long-term cost of GLP-1 treatment. We also look at 600,000 Medicare beneficiaries already enrolling in the $50 GLP-1 Bridge program, California’s effort to tackle affordability, the rapidly expanding oral GLP-1 market, and new real-world data on patients staying at lower doses of semaglutide and tirzepatide. The science is expanding. Access is contracting. And that may be the biggest challenge facing the next phase of the GLP-1 revolution. In this episode: • What the Fifth Circuit compounding decisions actually mean • FDA’s updated language around compounded GLP-1 vials • The 28-day multi-dose vial controversy • Mounjaro’s new cardiovascular indication • Why GLP-1s may reduce long-term healthcare costs • Employers dropping obesity-drug coverage • 600,000 people joining the Medicare GLP-1 Bridge • California’s push for lower GLP-1 prices • The oral GLP-1 race • New data on lower-dose semaglutide and tirzepatide Follow everything On The Pen: This episode is sponsored by VoaFit. https://www.voafit.com/otp This content is for informational and educational purposes only and is not medical advice. Always discuss medication and treatment decisions with a qualified healthcare professional.
September 02, 202625min